Pulmonary Hypertension: Intensification and Personalisation of Combination Rx
Status:
Not yet recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate the capacity of implantable/remote technology
for early evaluation of drug therapies in patients with pulmonary arterial hypertension
(PAH). The main question it aims to answer is whether structured changes in clinical therapy
will be detectable using implanted regulatory approved devices. Participants will will be
implanted with approved medical devices and will enter into a study of approved drugs to
assess physiology, activity and patient reported quality-of-life (QoL) outcomes. Researchers
will compare two therapeutic strategies in each individual patient to see if the study design
provides enough evidence to personalise drug treatment plans
Phase:
Phase 4
Details
Lead Sponsor:
Sheffield Teaching Hospitals NHS Foundation Trust
Collaborators:
University of Cambridge University of Glasgow University of Newcastle Upon-Tyne University of Sheffield